Healthcare Industry News: shingles
News Release - March 3, 2006
FermaVir Appoints Finance and Biotech Industry Executive Frederick Larcombe as Chief Financial OfficerVeteran Financial Officer Held Key Positions at Leading Pharmaceutical and Life Sciences Companies
NEW YORK--(HSMN NewsFeed)--March 3, 2006--FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR ), committed to the development of breakthrough antiviral and other drug therapies, announced the appointment of veteran financial and biotech industry executive Frederick Larcombe as Chief Financial Officer.
A financial executive and a Certified Public Accountant for more than 25 years, Mr. Larcombe brings to FermaVir a strong background in finance and strategic planning, with extensive expertise in the biotechnology and life sciences sectors. Mr. Larcombe currently serves as Chief Financial Officer of Xenomics, Inc., a developer of medical DNA technologies. He has recently served as CFO and Vice President of Finance at MicroDose Technologies, a developer of drug-delivery technology. He also served as Director of Commercial Development at Cambrex Corp., a life sciences company supporting the discovery and commercialization of therapeutics with more than $400,000,000 in annual revenues, where he helped direct a series of successful acquisitions.
As CFO of FermaVir, Mr. Larcombe's primary areas of responsibility will include management of the Company's financial matters, including accounting and reporting, taxation and auditing operations.
"FermaVir will benefit greatly from the deep experience and leadership that Fred Larcombe can bring to the Company and its mission to develop a range of important and medically valuable new drug therapies," said Dr. Geoffrey Henson, CEO of FermaVir. "Fred's skills as a senior financial executive will be an important addition to FermaVir's management team as we strive to move into our next phase of growth and accelerated efforts to develop our intellectual property portfolio and our drug candidate pipeline."
Mr. Larcombe began his career with PriceWaterhouseCoopers. His background consists of a variety of responsibilities with public and private companies, including experience in areas such as patent infringement litigation, international taxation, and acquisitions. He received his BS in Accounting from Seton Hall University and is a veteran of the Harvard Business School's Management Development Program.
"I look forward to becoming part of the FermaVir executive team and working with the Board of Directors to help the Company achieve its goals," said Mr. Larcombe. "FermaVir is distinguished not just by its promising drug development pipeline, but just as notably by the world-renowned scientists who make up its Board and management team."
FermaVir's lead drug candidates include powerful new antiviral compounds to treat shingles and Cytomegalovirus, potentially serious and often debilitating viral conditions that are part of the herpes family of diseases. The Company's proprietary drug compound to treat shingles is believed to be 10,000 times more potent than currently approved drug treatments. FermaVir's Board includes co-founder Professor Erik De Clercq, an inventor of some of the most important antiviral drug therapies sold today, and who is considered one of the world's leading experts on antiviral research.
About FermaVir Pharmaceuticals, Inc.
FermaVir Pharmaceuticals, Inc. is an emerging biotechnology company positioned for rapid growth by developing important antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. The Company's Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is a breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. FermaVir's proprietary compound is believed to be 10,000 times more potent than currently approved shingles drug treatments. FermaVir is also developing a compound that could provide the first improved effective treatment in years for Cytomegalovirus (CMV) infection, a currently incurable viral disease from the herpes family that can threaten eyesight as well as cause severe morbidity and mortality. For more investor-specific information about FermaVir, please visit http://www.trilogy-capital.com/tcp/fermavir. For detailed stock quote information, visit http://www.trilogy-capital.com/tcp/fermavir/quote.html. To view or download an Investor Fact Sheet about FermaVir, please visit http://www.trilogy-capital.com/tcp/fermavir/factsheet.html.
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although FermaVir believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of FermaVir, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that FermaVir will not obtain approval to market its products, the risk that FermaVir technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Source: FermaVir Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.